 |
|
 |
|
European Alpha1-antitrypsin Laurell’s Training Award (eALTA) 2007 submission process has started.
RESEARCH TRIANGLE PARK, N.C. and FRANKFURT, Germany (February 1, 2007) – Applicants are asked to submit a study proposal online at www.alta-award.com by March 15th 2007 detailing the research that they would like to conduct as part of the fellowship. The applications received will be evaluated by the eALTA scientific review team, which is comprised of five European experts in the field of alpha1-antitrypsin Deficiency and the Head of the European Medical department at Talecris Biotherapeutics, Dr. Marion Wencker. Applications will be assessed according to four assessment criteria: Scientific merit, innovation, impact of the project and quality of research environment.
“The European ALTA programme, which is supervised by dedicated experts at Talecris who were also instrumental in its establishment, is an important way in which we support current global research in the field of Alpha-1”, explained Alberto Martinez, M.D., Chairman and CEO of Talecris Biotherapeutics, during the awards ceremony at the European Respiratory Society conference in Munich. “Research initiatives such as eALTA improve not only our understanding of the condition and its treatment; they also increase the interest and involvement of young scientists and clinicians who represent the future of the Alpha-1 community.”
The programme was started in 2004 by Bayer HealthCare and is continued by Talecris Biotherapeutics. To date, almost 400,000 US Dollars have been provided for the purposes of setting up and supporting innovative scientific projects for young researchers and medical students.
eALTA in 2006
In September 2006, Talecris Biotherapeutics awarded the third European Alpha-1-Antitrypsin Laurell’s Training Award (eALTA). The eALTA 2006 winners are Ilaria Ferrarotti from the University of Pavia in Italy and A. Rembert Koczulla from the Philipps-Universität Marburg in Germany. The research projects of the two winners will each be supported for one year with 65,000 US Dollars.
Details of the application process and deadlines can be found at www.alta-award.com.
Contact:
Dr. med. Marion Wencker Talecris Biotherapeutics GmbH
Tel.: +49 (0) 69 - 660 593 301
Email: info@alta-award.com
Web: www.alta-award.com, www.talecris.com
About Talecris Biotherapeutics: Inspiration. Dedication. Innovation.
Talecris Biotherapeutics is a global biotherapeutic and biotechnology company that discovers, develops and produces critical care treatments for people with life-threatening disorders in a variety of therapeutic areas including immunology, pulmonology, and hemostasis. Talecris is proudly building upon a 60-year legacy of innovation and a commitment to improving the lives of people who rely on its therapeutic products. With an emphasis on scientific inquiry and technological excellence, Talecris is expanding its current portfolio of products, programs, and services through its own world-class product development organization as well as through strategic initiatives that leverage its strengths with those of its partners.
Talecris, with revenues of approximately $1.2 billion in 2007, is headquartered in biotech hub Research Triangle Park, N.C., and employs more than 4,000 talented people worldwide.
To learn more about Talecris and how our employees are making a difference in the lives of patients and the healthcare community, visit www.talecris.com.
Important Safety Information
Prolastin®, Alpha1-Proteinase Inhibitor (Human) is indicated for chronic replacement therapy of individuals having congenital deficiency of alpha-1 PI (alpha1-antitrypsin deficiency) with clinically demonstrable panacinar emphysema. Weekly Prolastin® therapy has demonstrated a low occurrence of side effects. In clinical studies with Prolastin®, reactions were observed in 1.16% of infusions, the most common events being fever (0.77%), light-headedness (0.19%), and dizziness (0.19%). As with all plasma-derived therapeutics, the potential to transmit infectious agents cannot be totally eliminated. Individuals with selective IgA deficiencies who have known antibody against IgA (anti-IgA antibody) should not receive Prolastin®, since these patients may experience severe reactions, including anaphylaxis, to IgA which may be present.
You are encouraged to report negative side effects of prescription drugs
to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.
Please click here for Prolastin® full Prescribing Information.
Remember, your doctor or healthcare provider is the single best source of information regarding you and your health. Please consult your doctor or healthcare provider if you have any questions about your health or any of your medications.
|
|
|
|
|